Item Text

20. PROOF OF CLAIM FOR IN RE WELLBUTRIN SR ANTITRUST LITIGATION, NO. 04-CV-5898 Approve the Proof of Claim submitted by Maricopa County on June 17, 2013 for inclusion in the settlement of a certified class action filed by other entities for reimbursement of overpayments made for certain brand-name prescription drugs. Authorize compromise of the claim in the amount of $4,674.54. This request concerns the lawsuit entitled In re Wellbutrin SR Antitrust Litigation, No. 04-CV-5898. The plaintiffs, direct and indirect purchasers of Wellbutrin XL, have sued Biovail and GSK for illegally conspiring to prevent generic versions of Wellbutrin XL from entering the American market by filing sham patent infringement lawsuits and a citizen petition with the Food and Drug Administration ("FDA"), and entering into agreements with generic companies to settle the lawsuits. The Defendant has entered into a $21.5 million Settlement. After deducting attorneys’ fees and expenses, service awards to the Class Representatives, and notice and administrative fees, the net fund will be distributed to Third Party Payers who made payments for Wellbutrin SR and/or its AB-rated generic equivalents and who submit a valid claim on time. Maricopa County filed a Proof of Claim on June 17, 2013. The class settlement provides for payment of Maricopa County’s claim in the amount of $4,674.54. The Board is requested to approve the Proof of Claim submitted and authorize the compromise of the claim in the amount of $4,674.54. (C-39-15-004-2-00)